1. Home
  2. ABUS vs IART Comparison

ABUS vs IART Comparison

Compare ABUS & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$4.71

Market Cap

884.7M

Sector

Health Care

ML Signal

N/A

Logo Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation

N/A

Current Price

$9.59

Market Cap

933.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ABUS
IART
Founded
2005
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
884.7M
933.9M
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
ABUS
IART
Price
$4.71
$9.59
Analyst Decision
Strong Buy
Hold
Analyst Count
1
7
Target Price
$5.00
$14.83
AVG Volume (30 Days)
2.2M
720.9K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
13.64
N/A
EPS
N/A
N/A
Revenue
$6,171,000.00
N/A
Revenue This Year
$125.30
$4.45
Revenue Next Year
N/A
$3.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.71
$9.37
52 Week High
$5.10
$24.37

Technical Indicators

Market Signals
Indicator
ABUS
IART
Relative Strength Index (RSI) 58.40 29.57
Support Level $4.18 N/A
Resistance Level $5.01 $14.14
Average True Range (ATR) 0.22 0.54
MACD 0.03 -0.18
Stochastic Oscillator 80.79 8.71

Price Performance

Historical Comparison
ABUS
IART

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Share on Social Networks: